Strategic Partnerships RayBiotech maintains active strategic alliances with Allumiqs and Venebio to connect its antibody array and ELISA platforms with multiomics data analytics. This enables customers to progress from discovery to IND enabling and CMC/clinical readiness within integrated workflows. The sales approach can emphasize co selling bundled solutions to pharma and CROs with a shared data ecosystem.

Global Translational Reach With a footprint in 85 countries and a portfolio that includes high density antibody arrays and ELISA platforms, RayBiotech is well suited to support global biomarker programs and CRO collaborations. This international reach can be leveraged to offer standardized assays, scalable production, and cross regional data handling and compliance.

High Density Advantage RayBiotech's 2000 target antibody array demonstrates RayBiotech's capacity for broad panels and multiplexed biomarker discovery. This capability can be offered as a premium service or bundled with analytics to attract academic lab customers and pharma programs seeking expansive marker panels and efficient sample usage.

Diagnostics Market Experience Past collaborations such as supplying rapid COVID-19 antibody test kits to retired NFL players demonstrate RayBiotech's ability to deliver rapid diagnostics for niche markets. This opens doors to sports medicine, occupational health, and patient monitoring programs where fast, validated assays are valued.

Funded Growth Opportunities RayBiotech has pursued funded collaborations, including a grant from the BIRD Foundation, signaling readiness to participate in joint funded programs with pharma, biotech, and CRO partners. This can translate into co development opportunities, grant driven projects, and clear ROI messaging that resonates with potential customers seeking funded translational biomarker research.